| 1 | The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature | Journal of Neuromuscular Diseases | 2015 | 275 |
| 2 | Current Classification and Management of Inflammatory Myopathies | Journal of Neuromuscular Diseases | 2018 | 246 |
| 3 | Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care | Journal of Neuromuscular Diseases | 2020 | 192 |
| 4 | Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening | Journal of Neuromuscular Diseases | 2018 | 182 |
| 5 | Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study | Journal of Neuromuscular Diseases | 2019 | 173 |
| 6 | Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials | Journal of Neuromuscular Diseases | 2016 | 163 |
| 7 | Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database | Journal of Neuromuscular Diseases | 2017 | 162 |
| 8 | AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort | Journal of Neuromuscular Diseases | 2019 | 155 |
| 9 | Gene Therapy for Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2021 | 154 |
| 10 | Increasing Role of Titin Mutations in Neuromuscular Disorders | Journal of Neuromuscular Diseases | 2016 | 145 |
| 11 | One Year of Newborn Screening for SMA – Results of a German Pilot Project | Journal of Neuromuscular Diseases | 2019 | 140 |
| 12 | Anti-HMGCR Myopathy | Journal of Neuromuscular Diseases | 2018 | 134 |
| 13 | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany | Journal of Neuromuscular Diseases | 2018 | 122 |
| 14 | Molecular Mechanisms of Skeletal Muscle Hypertrophy | Journal of Neuromuscular Diseases | 2021 | 121 |
| 15 | Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2 | Journal of Neuromuscular Diseases | 2020 | 119 |
| 16 | Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis | Journal of Neuromuscular Diseases | 2015 | 106 |
| 17 | Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles | Journal of Neuromuscular Diseases | 2016 | 99 |
| 18 | A Premature Stop Codon in MYO18B is Associated with Severe Nemaline Myopathy with Cardiomyopathy | Journal of Neuromuscular Diseases | 2015 | 94 |
| 19 | The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies | Journal of Neuromuscular Diseases | 2015 | 92 |
| 20 | Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial | Journal of Neuromuscular Diseases | 2021 | 91 |
| 21 | Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2019 | 89 |
| 22 | Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy | Journal of Neuromuscular Diseases | 2015 | 88 |
| 23 | Diaphragm: Pathophysiology and Ultrasound Imaging in Neuromuscular Disorders | Journal of Neuromuscular Diseases | 2018 | 88 |
| 24 | Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission | Journal of Neuromuscular Diseases | 2014 | 84 |
| 25 | Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy | Journal of Neuromuscular Diseases | 2017 | 84 |
| 26 | Exon-Skipping in Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2021 | 83 |
| 27 | Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview | Journal of Neuromuscular Diseases | 2015 | 80 |
| 28 | Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients | Journal of Neuromuscular Diseases | 2016 | 80 |
| 29 | Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area | Journal of Neuromuscular Diseases | 2015 | 77 |
| 30 | A Systematic Review and Meta-Analysis of Prevalence Studies of Sporadic Inclusion Body Myositis | Journal of Neuromuscular Diseases | 2017 | 72 |
| 31 | Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy | Journal of Neuromuscular Diseases | 2021 | 68 |
| 32 | Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials | Journal of Neuromuscular Diseases | 2022 | 68 |
| 33 | European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences | Journal of Neuromuscular Diseases | 2016 | 64 |
| 34 | Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience | Journal of Neuromuscular Diseases | 2021 | 61 |
| 35 | Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History | Journal of Neuromuscular Diseases | 2018 | 59 |
| 36 | Advancements in AAV-mediated Gene Therapy for Pompe Disease | Journal of Neuromuscular Diseases | 2020 | 59 |
| 37 | Sarcomere Dysfunction in Nemaline Myopathy | Journal of Neuromuscular Diseases | 2017 | 58 |
| 38 | Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism | Journal of Neuromuscular Diseases | 2015 | 57 |
| 39 | Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy | Journal of Neuromuscular Diseases | 2020 | 57 |
| 40 | Compliance to Care Guidelines for Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2015 | 56 |
| 41 | Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease – A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI | Journal of Neuromuscular Diseases | 2019 | 56 |
| 42 | Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening – Opportunity or Burden?1 | Journal of Neuromuscular Diseases | 2020 | 56 |
| 43 | Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients | Journal of Neuromuscular Diseases | 2015 | 55 |
| 44 | Current View of Diagnosing Small Fiber Neuropathy | Journal of Neuromuscular Diseases | 2021 | 54 |
| 45 | Prolonged Ambulation in Duchenne Patients with a Mutation Amenable to Exon 44 Skipping | Journal of Neuromuscular Diseases | 2014 | 53 |
| 46 | Current Translational Research and Murine Models For Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2016 | 53 |
| 47 | Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology | Journal of Neuromuscular Diseases | 2019 | 53 |
| 48 | Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy | Journal of Neuromuscular Diseases | 2022 | 53 |
| 49 | Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis | Journal of Neuromuscular Diseases | 2019 | 52 |
| 50 | Measuring Outcomes in Adults with Spinal Muscular Atrophy – Challenges and Future Directions – Meeting Report | Journal of Neuromuscular Diseases | 2020 | 51 |